Johnny Mahlangu

12.8k total citations · 5 hit papers
191 papers, 7.2k citations indexed

About

Johnny Mahlangu is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Johnny Mahlangu has authored 191 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Hematology, 52 papers in Genetics and 25 papers in Molecular Biology. Recurrent topics in Johnny Mahlangu's work include Hemophilia Treatment and Research (158 papers), Platelet Disorders and Treatments (61 papers) and Blood Coagulation and Thrombosis Mechanisms (57 papers). Johnny Mahlangu is often cited by papers focused on Hemophilia Treatment and Research (158 papers), Platelet Disorders and Treatments (61 papers) and Blood Coagulation and Thrombosis Mechanisms (57 papers). Johnny Mahlangu collaborates with scholars based in South Africa, United States and United Kingdom. Johnny Mahlangu's co-authors include Alok Srivastava, Adolfo Llinás, Johannes Oldenburg, Guy Young, Elena Santagostino, Midori Shima, Jerzy Windyga, Rebecca Kruse‐Jarres, Gallia G. Levy and Nigel S. Key and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Johnny Mahlangu

173 papers receiving 7.0k citations

Hit Papers

Guidelines for the management of hemophilia 2012 2026 2016 2021 2012 2020 2017 2018 2019 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines for the management of hemophilia
    2012 1.4k citations Alok Srivastava, Adolfo Llinás et al. Haemophilia profile →
  2. WFH Guidelines for the Management of Hemophilia, 3rd edition
    2020 1.1k citations Alok Srivastava, Elena Santagostino et al. Haemophilia profile →
  3. Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
  4. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →
  5. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    2019 263 citations Guy Young, Tiffany Chang et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johnny Mahlangu South Africa 35 6.6k 1.7k 1.0k 442 391 191 7.2k
Víctor Jiménez‐Yuste Spain 36 5.1k 0.8× 1.4k 0.9× 497 0.5× 233 0.5× 514 1.3× 266 5.8k
Maria Elisa Mancuso Italy 34 4.0k 0.6× 1.0k 0.6× 694 0.7× 243 0.5× 287 0.7× 178 4.6k
Manuel Carção Canada 34 3.8k 0.6× 874 0.5× 514 0.5× 215 0.5× 589 1.5× 188 4.5k
Rolf Ljung Sweden 42 4.8k 0.7× 1.2k 0.7× 1.1k 1.1× 160 0.4× 327 0.8× 170 5.3k
Paolo de Fabritiis Italy 32 1.8k 0.3× 814 0.5× 840 0.8× 708 1.6× 122 0.3× 199 3.2k
Francesco Lanza Italy 33 2.1k 0.3× 822 0.5× 804 0.8× 1.0k 2.3× 279 0.7× 159 3.8k
Guido Kobbe Germany 40 3.8k 0.6× 1.3k 0.8× 1.1k 1.1× 1.3k 3.0× 88 0.2× 204 5.2k
Hérvè Chambost France 32 2.2k 0.3× 469 0.3× 749 0.7× 600 1.4× 157 0.4× 134 3.8k
Sally Arai United States 35 2.4k 0.4× 548 0.3× 1.1k 1.1× 1.2k 2.8× 231 0.6× 149 4.4k
Margareth C. Ozelo Brazil 26 1.6k 0.2× 380 0.2× 1.0k 1.0× 535 1.2× 187 0.5× 122 2.8k

Countries citing papers authored by Johnny Mahlangu

Since Specialization
Citations

This map shows the geographic impact of Johnny Mahlangu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johnny Mahlangu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johnny Mahlangu more than expected).

Fields of papers citing papers by Johnny Mahlangu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johnny Mahlangu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johnny Mahlangu. The network helps show where Johnny Mahlangu may publish in the future.

Co-authorship network of co-authors of Johnny Mahlangu

This figure shows the co-authorship network connecting the top 25 collaborators of Johnny Mahlangu. A scholar is included among the top collaborators of Johnny Mahlangu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johnny Mahlangu. Johnny Mahlangu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matino, Davide, Andrew Palladino, Carrie Turich Taylor, et al.. (2025). Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 146(14). 1654–1663. 3 indexed citations
2.
Matino, Davide, Suchitra S. Acharya, Carrie Turich Taylor, et al.. (2025). Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 147(9). 920–931.
3.
4.
Mahlangu, Johnny, Víctor Jiménez‐Yuste, Markus Niggli, et al.. (2024). Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Research and Practice in Thrombosis and Haemostasis. 8(2). 102364–102364. 8 indexed citations
5.
Doxzen, Kevin, Jennifer E. Adair, Yris Maria Fonseca-Bazzo, et al.. (2024). The translational gap for gene therapies in low- and middle-income countries. Science Translational Medicine. 16(746). eadn1902–eadn1902. 20 indexed citations
6.
Miesbach, Wolfgang, Barbara A. Konkle, Pratima Chowdary, et al.. (2024). Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. Journal of Thrombosis and Haemostasis. 22(5). 1510–1515. 5 indexed citations
7.
Shapiro, Amy D., Roshni Kulkarni, Margaret V. Ragni, et al.. (2023). Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Advances. 7(13). 3049–3057. 4 indexed citations
8.
Mahlangu, Johnny, Susan Shapiro, Margareth C. Ozelo, et al.. (2023). Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis. Hämostaseologie. 43(S 01). S96–S96. 1 indexed citations
9.
Chowdary, Pratima, Margareta Holmström, Johnny Mahlangu, et al.. (2022). Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies. Research and Practice in Thrombosis and Haemostasis. 6(5). e12760–e12760. 11 indexed citations
10.
Kenet, Gili, Yeu‐Chin Chen, Gillian Lowe, et al.. (2021). Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine. 10(24). 5959–5959. 16 indexed citations
11.
Galen, Karin P. M. van, Roseline d’Oiron, Paula James, et al.. (2021). A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 19(8). 1883–1887. 91 indexed citations
12.
Srivastava, Alok, Elena Santagostino, Alison Dougall, et al.. (2020). WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 26(S6). 1–158. 1076 indexed citations breakdown →
13.
Pierce, Glenn F., John Pasi, Donna Coffin, et al.. (2020). Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 26(3). 443–449. 16 indexed citations
14.
Peyvandi, Flora, Johnny Mahlangu, Steven W. Pipe, et al.. (2020). Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis. 19. 32–41. 14 indexed citations
15.
Mancuso, Maria Elisa, Johnny Mahlangu, Robert F. Sidonio, et al.. (2020). Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study. Haemophilia. 26(6). 1009–1018. 18 indexed citations
16.
Mahlangu, Johnny, et al.. (2019). Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. South African Medical Journal. 109(9). 639–639. 3 indexed citations
17.
Nathwani, Amit C., Ulrike M. Reiss, Edward G. D. Tuddenham, et al.. (2018). Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer. Blood. 132(Supplement 1). 491–491. 94 indexed citations
18.
Oldenburg, Johannes, Roshni Kulkarni, Alok Srivastava, et al.. (2017). Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 24(1). 77–84. 38 indexed citations
19.
Mahlangu, Johnny, et al.. (2016). TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 22(6). 873–879. 21 indexed citations
20.
Escobar, Miguel A., Ramin Tehranchi, Faraizah Abdul Karim, et al.. (2016). Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX. Haemophilia. 23(1). 67–76. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Víctor Jiménez‐Yuste Breakdown of academic impact, for papers by Maria Elisa Mancuso Breakdown of academic impact, for papers by Manuel Carção Breakdown of academic impact, for papers by Rolf Ljung Breakdown of academic impact, for papers by Paolo de Fabritiis Breakdown of academic impact, for papers by Francesco Lanza Breakdown of academic impact, for papers by Guido Kobbe Breakdown of academic impact, for papers by Hérvè Chambost Breakdown of academic impact, for papers by Sally Arai Breakdown of academic impact, for papers by Margareth C. Ozelo
Rankless by CCL
2026